« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5
, Pages
990-996.e9
, November 2009
Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma
-
Total nitrite plus nitrate (A), nitrite (B), nitrate (C), and nitrotyrosine (D) concentrations (in micromoles per liter) in the proximal (black bars) and distal (gray bars) airway ELF. Data represent
Total nitrite plus nitrate (A), nitrite (B), nitrate (C), and nitrotyrosine (D) concentrations (in micromoles per liter) in the proximal (black bars) and distal (gray bars) airway ELF. Data represent means ± SEMs with adult control subjects (AC), pediatric control subjects (PC), subjects with mild-to-moderate asthma (MA), and subjects with severe asthma (SA). aP < .05 versus adult control subjects. bP < .05 versus pediatric control subjects.
-
Scatterplot depicting the relationship between total nitrite plus nitrate and nitrotyrosine concentrations (in micromoles per liter) in the proximal (black circles) and distal (gray circles) airway ELScatterplot depicting the relationship between total nitrite plus nitrate and nitrotyrosine concentrations (in micromoles per liter) in the proximal (black circles) and distal (gray circles) airway ELF. Data were logarithmically transformed.
-
Total nitrite plus nitrate (A), nitrite (B), nitrate (C), and nitrotyrosine (D) concentrations (in micromoles per liter) in the proximal (black bars) and distal (gray bars) in the raw BAL supernatant.Total nitrite plus nitrate (A), nitrite (B), nitrate (C), and nitrotyrosine (D) concentrations (in micromoles per liter) in the proximal (black bars) and distal (gray bars) in the raw BAL supernatant. Data were not adjusted for the urea dilution. Data represent means ± SEMs with adult control subjects (AC), pediatric control subjects (PC), subjects with mild-to-moderate asthma (MA), and subjects with severe asthma (SA). aP < .05 versus adult control subjects. bP < .05 versus pediatric control subjects.
Supported with funds from National Institutes of Health/National Institute of Nursing Research KO1 NR010548, National Institutes of Health/National Center for Research Resources K12 RR017643, and National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program RO1 HL69170.
Disclosure of potential conflict of interest: W. G. Teague is on the speakers' bureau for Merck and Co; receives research support from the National Institutes of Health/National Heart, Lung, and Blood Institute, the American Lung Association, and the Centers for Disease Control and Prevention; is on the review panel for the American Thoracic Society; and is on the advisory board for WESTAT–Children's Health Study. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01321-9
doi: 10.1016/j.jaci.2009.08.039
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5
, Pages
990-996.e9
, November 2009
